Lion TCR

Lion TCR is a clinical-stage biotechnology company dedicated to developing T-cell receptor (TCR)-T cell therapies to treat life-threatening viral infections and virus-associated cancers in Asia. In Asia, over 20% of new cancer cases each year are attributable to chronic infections, particularly the vast majority of liver cancer cases caused by chronic infection with the hepatitis B virus (HBV), which is highly prevalent in the region. After more than a decade of foundational research, product engineering and development, and evaluation through preclinical and clinical trials, the company has brought its proprietary product to world-leading standards. This product harnesses the power of the patient’s own immune system to eliminate HBV-related hepatocellular carcinoma.